156 related articles for article (PubMed ID: 37957370)
1. Zanubrutinib-lenalidomide-rituximab (ZR
Wang Y; Xu J; Li P; Xu Y; Xue H; Liu P
Ann Hematol; 2024 Feb; 103(2):499-510. PubMed ID: 37957370
[TBL] [Abstract][Full Text] [Related]
2. Chidamide with PEL regimen (prednisone, etoposide, lenalidomide) for elderly or frail patients with relapsed/refractory diffuse large B-Cell lymphoma -results of a single center, retrospective cohort in China.
Wang Y; Xue H; Song W; Xiao S; Jing F; Dong T; Wang L
Hematol Oncol; 2022 Oct; 40(4):617-625. PubMed ID: 35165928
[TBL] [Abstract][Full Text] [Related]
3. Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL.
Goy A; Ramchandren R; Ghosh N; Munoz J; Morgan DS; Dang NH; Knapp M; Delioukina M; Kingsley E; Ping J; Beaupre DM; Neuenburg JK; Ruan J
Blood; 2019 Sep; 134(13):1024-1036. PubMed ID: 31331917
[TBL] [Abstract][Full Text] [Related]
4. Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option?
Mondello P; Steiner N; Willenbacher W; Ferrero S; Ghione P; Marabese A; Pitini V; Cuzzocrea S; Mian M
Oncologist; 2016 Sep; 21(9):1107-12. PubMed ID: 27382029
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of lenalinomide combined with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma.
Ivanov V; Coso D; Chetaille B; Esterni B; Olive D; Aurran-Schleinitz T; Schiano JM; Stoppa AM; Broussais-Guillaumot F; Blaise D; Bouabdallah R
Leuk Lymphoma; 2014 Nov; 55(11):2508-13. PubMed ID: 24506467
[TBL] [Abstract][Full Text] [Related]
6. Zanubrutinib plus salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma.
Yuan X; Li X; Huang Y; Jin X; Liu H; Zhao A; Zhang W; Qian W; Liang Y
Front Immunol; 2022; 13():1015081. PubMed ID: 36505470
[TBL] [Abstract][Full Text] [Related]
7. Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma.
Yang H; Xiang B; Song Y; Zhang H; Zhao W; Zou D; Lv F; Guo W; Liu A; Li C; Tan Z; Liu Y; Fu L; Guo H; Novotny W; Huang J; Li Y
Blood Adv; 2022 Mar; 6(6):1629-1636. PubMed ID: 34638136
[TBL] [Abstract][Full Text] [Related]
8. Tafasitamab Plus Lenalidomide Versus 3 Rituximab-Based Treatments for Non-Transplant Eligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Matching-Adjusted Indirect Comparison.
Cordoba R; Prawitz T; Westley T; Sharma A; Ambarkhane S; Kapetanakis V; Sabatelli L
Adv Ther; 2022 Jun; 39(6):2668-2687. PubMed ID: 35403948
[TBL] [Abstract][Full Text] [Related]
9. Ibrutinib, rituximab, and lenalidomide in unfit or frail patients aged 75 years or older with de novo diffuse large B-cell lymphoma: a phase 2, single-arm study.
Xu PP; Shi ZY; Qian Y; Cheng S; Zhu Y; Jiang L; Li JF; Fang H; Huang HY; Yi HM; Ouyang BS; Wang L; Zhao WL
Lancet Healthy Longev; 2022 Jul; 3(7):e481-e490. PubMed ID: 36102758
[TBL] [Abstract][Full Text] [Related]
10. A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Czuczman MS; Trněný M; Davies A; Rule S; Linton KM; Wagner-Johnston N; Gascoyne RD; Slack GW; Brousset P; Eberhard DA; Hernandez-Ilizaliturri FJ; Salles G; Witzig TE; Zinzani PL; Wright GW; Staudt LM; Yang Y; Williams PM; Lih CJ; Russo J; Thakurta A; Hagner P; Fustier P; Song D; Lewis ID
Clin Cancer Res; 2017 Aug; 23(15):4127-4137. PubMed ID: 28381416
[No Abstract] [Full Text] [Related]
11. Efficacy and safety of zanubrutinib plus R-CHOP in treatment of non-GCB DLBCL with extranodal involvement.
Geng H; Jia S; Zhang Y; Li J; Yang Q; Zeng L; Zong X; Lu Y; Lu S; Zhou J; Li C; Wu D
Front Immunol; 2023; 14():1219167. PubMed ID: 37671152
[TBL] [Abstract][Full Text] [Related]
12. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.
Nowakowski GS; LaPlant B; Macon WR; Reeder CB; Foran JM; Nelson GD; Thompson CA; Rivera CE; Inwards DJ; Micallef IN; Johnston PB; Porrata LF; Ansell SM; Gascoyne RD; Habermann TM; Witzig TE
J Clin Oncol; 2015 Jan; 33(3):251-7. PubMed ID: 25135992
[TBL] [Abstract][Full Text] [Related]
13. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial.
Wang M; Fowler N; Wagner-Bartak N; Feng L; Romaguera J; Neelapu SS; Hagemeister F; Fanale M; Oki Y; Pro B; Shah J; Thomas S; Younes A; Hosing C; Zhang L; Newberry KJ; Desai M; Cheng N; Badillo M; Bejarano M; Chen Y; Young KH; Champlin R; Kwak L; Fayad L
Leukemia; 2013 Sep; 27(9):1902-9. PubMed ID: 23545991
[TBL] [Abstract][Full Text] [Related]
14. Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.
Thieblemont C; Tilly H; Gomes da Silva M; Casasnovas RO; Fruchart C; Morschhauser F; Haioun C; Lazarovici J; Grosicka A; Perrot A; Trotman J; Sebban C; Caballero D; Greil R; van Eygen K; Cohen AM; Gonzalez H; Bouabdallah R; Oberic L; Corront B; Choufi B; Lopez-Guillermo A; Catalano J; Van Hoof A; Briere J; Cabeçadas J; Salles G; Gaulard P; Bosly A; Coiffier B
J Clin Oncol; 2017 Aug; 35(22):2473-2481. PubMed ID: 28426350
[TBL] [Abstract][Full Text] [Related]
15. Rituximab, lenalidomide and BTK inhibitor as frontline treatment for elderly or unfit patients with diffuse large B-cell lymphoma: a real-world analysis of single center.
Zhu Y; Zhang X; Wei J; Yang C; Tong H; Mai W; Yang M; Qian J; Mao L; Meng H; Jin J; Yu W
Exp Hematol Oncol; 2022 Sep; 11(1):57. PubMed ID: 36114573
[TBL] [Abstract][Full Text] [Related]
16. [Programmed cell death-1 inhibitor combined with rituximab in refractory or relapsed diffuse large B-cell lymphoma: a preliminary efficacy and safety analysis].
Qin Y; Zhao FY; Zhou Y; Jiang SY; Yang S; Shi YK
Zhonghua Zhong Liu Za Zhi; 2020 Dec; 42(12):1034-1039. PubMed ID: 33342160
[No Abstract] [Full Text] [Related]
17. Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 study from GELTAMO.
Martín García-Sancho A; Baile M; Rodríguez G; Dlouhy I; Sancho JM; Jarque I; González-Barca E; Salar A; Espeso M; Grande C; Bergua J; Montes-Moreno S; Redondo A; Enjuanes A; Campo E; López-Guillermo A; Caballero D
Br J Haematol; 2023 Oct; 203(2):202-211. PubMed ID: 37485564
[TBL] [Abstract][Full Text] [Related]
18. Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial.
Jerkeman M; Eskelund CW; Hutchings M; Räty R; Wader KF; Laurell A; Toldbod H; Pedersen LB; Niemann CU; Dahl C; Kuitunen H; Geisler CH; Grønbæk K; Kolstad A
Lancet Haematol; 2018 Mar; 5(3):e109-e116. PubMed ID: 29396091
[TBL] [Abstract][Full Text] [Related]
19. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial.
Tam CS; Brown JR; Kahl BS; Ghia P; Giannopoulos K; Jurczak W; Šimkovič M; Shadman M; Österborg A; Laurenti L; Walker P; Opat S; Chan H; Ciepluch H; Greil R; Tani M; Trněný M; Brander DM; Flinn IW; Grosicki S; Verner E; Tedeschi A; Li J; Tian T; Zhou L; Marimpietri C; Paik JC; Cohen A; Huang J; Robak T; Hillmen P
Lancet Oncol; 2022 Aug; 23(8):1031-1043. PubMed ID: 35810754
[TBL] [Abstract][Full Text] [Related]
20. Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study.
Desai SH; LaPlant B; Macon WR; King RL; Wang Y; Inwards DJ; Micallef I; Johnston PB; Porrata LF; Ansell SM; Habermann TM; Witzig TE; Nowakowski GS
Blood Cancer J; 2021 Sep; 11(9):160. PubMed ID: 34564694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
